Confoundle · a reasoning trap

Publication bias

Search the medical literature on a drug and you are not seeing the research that was done. You are seeing the research that got written up and accepted, and studies that found something clear survive that filter much better than studies that found nothing. For one class of drugs the regulator's complete archive showed about half the trials were positive, while the journals showed nearly all of them. Nobody had to lie for that to happen. The disappointing ones simply never got finished.

The rule

The published literature is not a sample of the research done. It is the research that someone chose to submit and someone chose to print, and success survives that filter far better than failure.

What it looks like

Read the journals and almost every trial of these drugs worked. How many actually did?Twelve antidepressants, and every trial run to get them approved had to be registered with the American regulator before it began. That registry is the rare thing in medicine: a complete list, including the trials nobody ever wrote up. Go to the medical journals instead and you find 51 published trials, of which 48 read as positive.
Half. A coin flip, printed as a near-certainty.The regulator judged 38 of the 74 trials positive and 36 not. Of those 36, twenty two were never published at all. Eleven more did reach print, but reading as a positive result. So a doctor searching the literature finds 48 positive trials out of 51 and concludes the case is overwhelming, when the complete record says it was close to even:

Two of those judgements belong to different people, and it matters. Positive or negative was the regulator's own decision on the outcome each trial had promised to measure in advance. The reading that eleven publications conveyed a positive result was the study authors' assessment, not the regulator's, and they said so. What is not a matter of opinion is the twenty two that never appeared.

Why it works

Nothing here requires anyone to lie. A trial that finds nothing is duller to write up, harder to place, and commercially unwelcome, so it drifts to the bottom of the pile and quietly never gets finished. Repeat that across a field and the surviving literature is systematically sunnier than the research was. The effect compounds, because reviews and guidelines are built on what was published, so the gap is inherited by everything downstream and looks like accumulating evidence rather than a filter. Two things push back. The first is registration: declare the trial and its primary outcome before you start, and an unpublished result leaves a visible hole rather than no trace. The second is the funnel plot, which exploits the fact that small studies scatter widely and large ones cluster; if the small studies that should have landed on the disappointing side are missing, the scatter comes out lopsided. Neither fix works retrospectively on a literature that predates them, which is why the regulator's archive was the only way to answer this question at all.

Source

Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-260. Counts are Table 1 (p. 255) and Figure 1A (p. 256): of 74 registered trials, the FDA judged 38 positive; 40 publications agreed with the FDA, 11 conflicted by reading as positive, and 23 were never published.

See if it fools you

This page gives the answer away. The puzzle version shows you the same figures first and asks you to commit before the reveal.

Play this one